TY - JOUR A1 - Mehnert, Anja A1 - Koch, Uwe A1 - Schulz, Holger A1 - Wegscheider, Karl A1 - Weis, Joachim A1 - Faller, Hermann A1 - Keller, Monika A1 - Brähler, Elmar A1 - Härter, Martin T1 - Prevalence of mental disorders, psychosocial distress and need for psychosocial support in cancer patients – study protocol of an epidemiological multi-center study N2 - Background Empirical studies investigating the prevalence of mental disorders and psychological distress in cancer patients have gained increasing importance during recent years, particularly with the objective to develop and implement psychosocial interventions within the cancer care system. Primary purpose of this epidemiological cross-sectional multi-center study is to detect the 4-week-, 12-month-, and lifetime prevalence rates of comorbid mental disorders and to further assess psychological distress and psychosocial support needs in cancer patients across all major tumor entities within the in- and outpatient oncological health care and rehabilitation settings in Germany. Methods/Design In this multicenter, epidemiological cross-sectional study, cancer patients across all major tumor entities will be enrolled from acute care hospitals, outpatient cancer care facilities, and rehabilitation centers in five major study centers in Germany: Freiburg, Hamburg, Heidelberg, Leipzig and Würzburg. A proportional stratified random sample based on the nationwide incidence of all cancer diagnoses in Germany is used. Patients are consecutively recruited in all centers. On the basis of a depression screener (PHQ-9) 50% of the participants that score below the cutoff point of 9 and all patients scoring above are assessed using the Composite International Diagnostic Interview for Oncology (CIDI-O). In addition, all patients complete validated questionnaires measuring emotional distress, information and psychosocial support needs as well as quality of life. Discussion Epidemiological data on the prevalence of mental disorders and distress provide detailed and valid information for the estimation of the demands for the type and extent of psychosocial support interventions. The data will provide information about specific demographic, functional, cancer- and treatment-related risk factors for mental comorbidity and psychosocial distress, specific supportive care needs and use of psychosocial support offers. KW - metaanalysis KW - depression KW - survivors KW - care KW - sample KW - instrument KW - quality-of-life KW - generalized anxiety disorder KW - cooperative-oncology-group KW - decision making Y1 - 2012 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-153296 VL - 12 IS - 70 ER - TY - THES A1 - Schulz, Martin T1 - Einsatz des ITW Würzburg unter besonderer Beachtung der Beatmung T1 - Use of the mobile intensiv care unit Wurzburg with particular attention to artificial ventilation N2 - Es wurden die Einsätze des ITW Würzburg des Jahres 2005 anhand der vorhandenen Intensivtransportprotokolle ausgewertet. Ziel der Arbeit war eine quantitative und qualitative Bestandsaufnahme des Interhospitalverkehrs unter besonderer Beachtung des Beatmungsmanagements. Insgesamt wurden 249 reine ITW-Einsätze im Jahr 2005 gefahren, von denen 243 durch ein vorhandenes Intensivtransportprotokoll dokumentiert waren. Die Dokumentation des Intensivtransportprotokolls war recht different. Zum einen hing die Qualität der Dokumentation vom transportbegleiteten Arzt ab und zum anderen wiesen einzelne Bereiche des Protokolls eine schlechtere Dokumentation auf als andere. Insgesamt waren Scores oder Angaben, die verschlüsselt einzutragen waren durchweg schlechter dokumentiert. Außerdem wurden viele Angaben im Übernahmestatus nicht dokumentiert, da diese oft schon im Verlaufsprotokoll protokolliert waren, was allerdings die digitale Erfassung erschwerte. Aufgrund dieser Beobachtungen entstand der Eindruck, dass hier ein Bedarf zur Vereinfachung des Protokolls besteht. Die Einsatzfrequenz war mit 0,68 Einsätzen pro Tag relativ gering, was mit dem großen Einsatzbereich und der geringen Einwohner-, und Krankenhausdichte zusammenhängt. Der ITW Würzburg wurde vorwiegend während der regulären Vorbehaltszeiten genutzt. Nur ein geringer Anteil (<10%) der Einsätze fanden außerhalb dieser Zeiten statt. Die Gesamteinsatzdauer im Median betrug 3 Std. 30 Min. pro ITW-Einsatz. Der längste Einsatzabschnitt war dabei die Nachbereitungszeit mit 1 Std. 15 Min. im Median. Sie beinhaltete sowohl die Wiederherstellung der Einsatzbereitschaft des Fahrzeugs, sowie die Rückfahrt zum Standort und Pausen. Der kürzeste Einsatzabschnitt war die Behandlungszeit vor Ort mit 30 Minuten im Median. Dabei fiel auf, dass zentripetale Transporte signifikant längere Behandlungszeiten vor Ort erforderten als zentrifugale Transporte. Nur 67,5% der Einsätze erreichten den Patienten innerhalb einer Stunde. Um eine Eintreffzeit von einer Stunde zu realisieren, wären mindestens zwei weitere ITW-Standorte in Schweinfurt und Aschaffenburg nötig. Dies erscheint aber vor dem Hintergrund der Auslastung des ITW Würzburgs, der geringen Zahl an Sofort-transporten und der Kosten nicht adäquat. Drei Viertel aller Transporte waren Ferntransporte, mit einer durchschnittlichen Entfernung der Zielklinik von 72 Km. Hier erscheint der Standort Würzburg hinsichtlich der guten Verkehrsanbindung als zentraler Standort des ITWs sinnvoll. Zentripetale und zentrifugale Transporte waren annähernd gleich vertreten. Das Patientenkollektiv des ITW Würzburg entsprach dem auf Intensivstationen. Knapp dreiviertel der Patienten war über 50 Jahre alt. Insgesamt überwog der Anteil der männlichen Patienten. Am häufigsten wurden Patienten mit intrakraniellen Blutungen, zerebralen Ischämien und Schädelhirntraumen transportiert. Dieser Gruppe folgten Patienten mit akutem Koronarsyndrom und Patienten mit Sepsis. Über die Hälfte, der mit dem ITW Würzburg transportierten Patienten, waren beatmungspflichtig. Dabei fiel auf, dass unabhängig von der Transportart, die Zahl der BIPAP beatmeten Patienten zunahm. Am stärksten war dieser Anstieg bei den zentrifugalen Transporten. Der PEEP wurde bei zentripetalen Transporten signifikant öfters erhöht als bei zentrifugalen oder zentri-zentralen Transporten, was wie schon die Behandlungszeit vor Ort, auf eine intensivere Therapie schließen lässt. Die Strukturqualität des ITW Würzburgs in Form von Ausstattung und Personal wird den geforderten Standards gerecht. Gerade vor dem Hintergrund des Patientenkollektivs kommt der Ausstattung des ITWs und der Qualifikation des Personals eine entscheidende Bedeutung zu. Bestehende Standards dürfen im Hinblick auf eine adäquate Versorgung der Patienten nicht unterschritten werden. Verbesserungsbedarf besteht lediglich hinsichtlich der Prozessqualität. Dies gilt insbesondere für die Dokumentation, die entsprechenden Dokumentationswerkzeuge und die Auslastung des ITW Würzburgs. Hinsichtlich der Dokumentation ist eine möglichst zeitnahe elektronische Doku-mentation wünschenswert mit Ausbau der im Rahmen dieser Arbeit erstellten Datenbank. Was die Auslastung des ITW betrifft, so ist sicherlich noch Potential vorhanden, das es auszuschöpfen gilt. Hier ist eine bessere Informationspolitik über die Vorteile und Einsatzmöglichkeiten des ITWs von Nöten. Das Beatmungsmanagement zeigte eine Intensivierung der Beatmung vor allem bei zentripetalen Transporten, was die Bedeutung des ITWs als Teil der Intensiv-medizinischen Versorgung unterstreicht. N2 - The employments of the ITW Wurzburg of the yearly 2005 were evaluated on the basis existing intensive transportation minutes. A goal of the work was a quantitative and qualitative stocktaking of interhospital traffic special considering the artificially respirating management. Altogether 249 pure ITW employments were driven in the year 2005, from which 243 had documented by existing intensive transportation minutes. The documentation of intensive transportation minutes was quite different. The documentation depended on the transport-accompanied physician. Altogether were Scores or data, which were to be registered coded throughout more badly documented. In addition many data in the assumption status were not documented, since these were logged often already in process minutes, which made however the digital collection more difficult. Due to these observations the impression developed that a need exists here for the simplification of minutes. The employment frequency was relatively small with 0,68 employments per day, which is connected with the large area of application and the small inhabitants -, and hospital density. The ITW Wurzburg was predominantly used during the regular reservation times. Only a small portion (<10%)the employments took place outside of these times. The total length of application in the median amounted to 3 h 30 min. per ITW employment. The longest employment section was thereby the reinforcement time with 1 h 15 min. in the median. It contained both the re-establishment of the readiness of application of the vehicle, as well as the return trip for the location and tracing. The shortest employment section was the treatment time locally with 30 minutes in the median. It was noticeable that centripetal transportation required significantly longer treatment times than centrifugal transportation. Only 67.5% of the transports reached the patients within one hour. In order to realize a time up to one hour to reach the patients, at least two further ITW locations would be necessary in Schweinfurt and Aschaffenburg. This appears however considering the extent of utilization of the ITW Würzburg, the small number of immediately transportation and the costs, not adequately. Three quarters of all transportation were long-distance haulage, with an average distance of the goal hospital of 72 km. Centripetal and centrifugal transportation were approximately equally represented. The patient collective of the ITW Würzburg corresponded on intensive care units. Three-quater of the patients were older than 50 years. Altogether the portion of the male patients outweighed. Most frequently patients with intracranial bleedings, cerebral ischemia and head injuries were transported. This group patients with acute coronary syndrome and patients with Sepsis followed. Over half of the patients, transportet with the ITW Wurzburg, required artificial ventilation. It was noticeable that independently of the mode of transportation, the number of the BIPAP respirated patients increased. This rise was strongest in the case of the centrifugal transportation. The PEEP in the case of centripetal transportation was significantly more often increased as in the case of centrifugal or central-central transportation, which suggests like already the treatment time, a more intensive therapy. The structure quality of the ITW Wurzburg considering equipment and staff fullfill the demanded standards. Especially considering the patient collective, equipment and qualification of the staff have a crucial meaning. Existing standards may not be fallen below regarding an adequate supply of the patients. Improvement need exists only regarding the process quality. This applies in particular to the documentation, the appropriate documentation tools and the extent of utilization of the ITW Wurzburg. Regarding the documentation a time near electronic documentation is desirably with development in the framework this work provided Data base. Concerning the extent of utilization of the ITW, there is surely still potential. Here is a better information policy over the advantages and application of the ITWs usefull. The artificially respirating management showed an intensification of the artificial respiration particularly in the case of centripetal transportation, which underlines the meaning of the ITWs as part of the intensive-medical supply. KW - Notfallmedizin KW - Künstliche Beatmung KW - Intensivtransport KW - ITW KW - Qualitätsmanagement KW - Mobile intensive care unit KW - ventilation Y1 - 2007 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-25784 ER - TY - JOUR A1 - Semmler, Anna-Lena A1 - Sacconi, Sabrina A1 - Bach, J. Elisa A1 - Liebe, Claus A1 - Bürmann, Jan A1 - Kley, Rudolf A. A1 - Ferbert, Andreas A1 - Anderheiden, Roland A1 - Van den Bergh, Peter A1 - Martin, Jean-Jacques A1 - De Jonghe, Peter A1 - Neuen-Jacob, Eva A1 - Müller, Oliver A1 - Deschauer, Marcus A1 - Bergmann, Markus A1 - Schröder, J. Michael A1 - Vorgerd, Matthias A1 - Schulz, Jörg B. A1 - Weis, Joachim A1 - Kress, Wolfram A1 - Claeys, Kristl G. T1 - Unusual multisystemic involvement and a novel BAG3 mutation revealed by NGS screening in a large cohort of myofibrillar myopathies JF - Orphanet Journal of Rare Diseases N2 - Background: Myofibrillar myopathies (MFM) are a group of phenotypically and genetically heterogeneous neuromuscular disorders, which are characterized by protein aggregations in muscle fibres and can be associated with multisystemic involvement. Methods: We screened a large cohort of 38 index patients with MFM for mutations in the nine thus far known causative genes using Sanger and next generation sequencing (NGS). We studied the clinical and histopathological characteristics in 38 index patients and five additional relatives (n = 43) and particularly focused on the associated multisystemic symptoms. Results: We identified 14 heterozygous mutations (diagnostic yield of 37%), among them the novel p. Pro209Gln mutation in the BAG3 gene, which was associated with onset in adulthood, a mild phenotype and an axonal sensorimotor polyneuropathy, in the absence of giant axons at the nerve biopsy. We revealed several novel clinical phenotypes and unusual multisystemic presentations with previously described mutations: hearing impairment with a FLNC mutation, dysphonia with a mutation in DES and the first patient with a FLNC mutation presenting respiratory insufficiency as the initial symptom. Moreover, we described for the first time respiratory insufficiency occurring in a patient with the p. Gly154Ser mutation in CRYAB. Interestingly, we detected a polyneuropathy in 28% of the MFM patients, including a BAG3 and a MYOT case, and hearing impairment in 13%, including one patient with a FLNC mutation and two with mutations in the DES gene. In four index patients with a mutation in one of the MFM genes, typical histological findings were only identified at the ultrastructural level (29%). Conclusions: We conclude that extraskeletal symptoms frequently occur in MFM, particularly cardiac and respiratory involvement, polyneuropathy and/or deafness. BAG3 mutations should be considered even in cases with a mild phenotype or an adult onset. We identified a genetic defect in one of the known genes in less than half of the MFM patients, indicating that more causative genes are still to be found. Next generation sequencing techniques should be helpful in achieving this aim. KW - polyneuropathy KW - MFM KW - next generation sequencing KW - bcl-2 associated athanogene protein 3 KW - protein aggregation KW - hearing impairment KW - early respiratory-failure KW - myopathy KW - muscular-dystrophy KW - skeletal myopathy Y1 - 2014 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-115623 SN - 1750-1172 N1 - Additional files are available here: http://www.ojrd.com/content/9/1/121/additional VL - 9 IS - 121 ER - TY - JOUR A1 - Bäuerlein, Carina A. A1 - Riedel, Simone S. A1 - Baker, Jeanette A1 - Brede, Christian A1 - Jordán Garrote, Ana-Laura A1 - Chopra, Martin A1 - Ritz, Miriam A1 - Beilhack, Georg F. A1 - Schulz, Stephan A1 - Zeiser, Robert A1 - Schlegel, Paul G. A1 - Einsele, Hermann A1 - Negrin, Robert S. A1 - Beilhack, Andreas T1 - A diagnostic window for the treatment of acute graft-versus-host disease prior to visible clinical symptoms in a murine model JF - BMC Medicine N2 - Background Acute graft-versus-host disease (aGVHD) poses a major limitation for broader therapeutic application of allogeneic hematopoietic cell transplantation (allo-HCT). Early diagnosis of aGVHD remains difficult and is based on clinical symptoms and histopathological evaluation of tissue biopsies. Thus, current aGVHD diagnosis is limited to patients with established disease manifestation. Therefore, for improved disease prevention it is important to develop predictive assays to identify patients at risk of developing aGVHD. Here we address whether insights into the timing of the aGVHD initiation and effector phases could allow for the detection of migrating alloreactive T cells before clinical aGVHD onset to permit for efficient therapeutic intervention. Methods Murine major histocompatibility complex (MHC) mismatched and minor histocompatibility antigen (miHAg) mismatched allo-HCT models were employed to assess the spatiotemporal distribution of donor T cells with flow cytometry and in vivo bioluminescence imaging (BLI). Daily flow cytometry analysis of peripheral blood mononuclear cells allowed us to identify migrating alloreactive T cells based on homing receptor expression profiles. Results We identified a time period of 2 weeks of massive alloreactive donor T cell migration in the blood after miHAg mismatch allo-HCT before clinical aGVHD symptoms appeared. Alloreactive T cells upregulated α4β7 integrin and P-selectin ligand during this migration phase. Consequently, targeted preemptive treatment with rapamycin, starting at the earliest detection time of alloreactive donor T cells in the peripheral blood, prevented lethal aGVHD. Conclusions Based on this data we propose a critical time frame prior to the onset of aGVHD symptoms to identify alloreactive T cells in the peripheral blood for timely and effective therapeutic intervention. KW - Allogeneic stem cell transplantation KW - Graft-versus-host disease KW - Minor histocompatibility antigen mismatch transplantation Y1 - 2013 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-96797 UR - http://www.biomedcentral.com/1741-7015/11/134 ER - TY - JOUR A1 - Esser, Peter A1 - Mehnert‐Theuerkauf, Anja A1 - Friedrich, Michael A1 - Johansen, Christoffer A1 - Brähler, Elmar A1 - Faller, Hermann A1 - Härter, Martin A1 - Koch, Uwe A1 - Schulz, Holger A1 - Wegscheider, Karl A1 - Weis, Joachim A1 - Kuba, Katharina A1 - Hinz, Andreas A1 - Hartung, Tim T1 - Risk and associated factors of depression and anxiety in men with prostate cancer: Results from a German multicenter study JF - Psycho‐Oncology N2 - Objective In order to optimize psycho‐oncological care, studies that quantify the extent of distress and identify certain risk groups are needed. Among patients with prostate cancer (PCa), findings on depression and anxiety are limited. Methods We analyzed data of PCa patients selected from a German multi‐center study. Depression and anxiety were assessed with the PHQ‐9 and the GAD‐7 (cut‐off ≥7). We provided physical symptom burden, calculated absolute and relative risk (AR and RR) of depression and anxiety across patient subsets and between patients and the general population (GP) and tested age as a moderator within the relationship of disease‐specific symptoms with depression and anxiety. Results Among 636 participants, the majority reported disease‐specific problems (sexuality: 60%; urination: 52%). AR for depression and anxiety was 23% and 22%, respectively. Significant RR were small, with higher risks of distress in patients who are younger (eg, RR\(_{depression}\) = 1.15; 95%‐CI: 1.06‐1.26), treated with chemotherapy (RR\(_{depression}\)n = 1.46; 95%‐CI: 1.09‐1.96) or having metastases (RR\(_{depression}\) = 1.30; 95%‐CI: 1.02‐1.65). Risk of distress was slightly elevated compared to GP (eg, RR\(_{depression}\) = 1.13; 95%‐CI: 1.07‐1.19). Age moderated the relationship between symptoms and anxiety (B\(_{urination}\) = −0.10, P = .02; B\(_{sexuality}\) = −0.11, P = .01). Conclusions Younger patients, those with metastases or treatment with chemotherapy seem to be at elevated risk for distress and should be closely monitored. Many patients suffer from disease‐specific symptom burden, by which younger patients seem to be particularly distressed. Support of coping mechanisms associated with disease‐specific symptom burden seems warranted. KW - anxiety KW - cancer KW - depression KW - oncology KW - prostatic neoplasms Y1 - 2020 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-218277 VL - 29 IS - 10 SP - 1604 EP - 1612 ER - TY - JOUR A1 - Feldheim, Jonas A1 - Kessler, Almuth F. A1 - Feldheim, Julia J. A1 - Schulz, Ellina A1 - Wend, David A1 - Lazaridis, Lazaros A1 - Kleinschnitz, Christoph A1 - Glas, Martin A1 - Ernestus, Ralf-Ingo A1 - Brandner, Sebastian A1 - Monoranu, Camelia M. A1 - Löhr, Mario A1 - Hagemann, Carsten T1 - Effects of long-term temozolomide treatment on glioblastoma and astrocytoma WHO grade 4 stem-like cells JF - International Journal of Molecular Sciences N2 - Glioblastoma leads to a fatal course within two years in more than two thirds of patients. An essential cornerstone of therapy is chemotherapy with temozolomide (TMZ). The effect of TMZ is counteracted by the cellular repair enzyme O\(^6\)-methylguanine-DNA methyltransferase (MGMT). The MGMT promoter methylation, the main regulator of MGMT expression, can change from primary tumor to recurrence, and TMZ may play a significant role in this process. To identify the potential mechanisms involved, three primary stem-like cell lines (one astrocytoma with the mutation of the isocitrate dehydrogenase (IDH), CNS WHO grade 4 (HGA)), and two glioblastoma (IDH-wildtype, CNS WHO grade 4) were treated with TMZ. The MGMT promoter methylation, migration, proliferation, and TMZ-response of the tumor cells were examined at different time points. The strong effects of TMZ treatment on the MGMT methylated cells were observed. Furthermore, TMZ led to a loss of the MGMT promoter hypermethylation and induced migratory rather than proliferative behavior. Cells with the unmethylated MGMT promoter showed more aggressive behavior after treatment, while HGA cells reacted heterogenously. Our study provides further evidence to consider the potential adverse effects of TMZ chemotherapy and a rationale for investigating potential relationships between TMZ treatment and change in the MGMT promoter methylation during relapse. KW - glioblastoma KW - astrocytoma KW - IDH KW - MGMT KW - therapy KW - temozolomide KW - cancer stem cells Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-284417 SN - 1422-0067 VL - 23 IS - 9 ER - TY - JOUR A1 - Bonig, Halvard A1 - Kuçi, Zyrafete A1 - Kuçi, Selim A1 - Bakhtiar, Shahrzad A1 - Basu, Oliver A1 - Bug, Gesine A1 - Dennis, Mike A1 - Greil, Johann A1 - Barta, Aniko A1 - Kállay, Krisztián M. A1 - Lang, Peter A1 - Lucchini, Giovanna A1 - Pol, Raj A1 - Schulz, Ansgar A1 - Sykora, Karl-Walter A1 - Teichert von Luettichau, Irene A1 - Herter-Sprie, Grit A1 - Ashab Uddin, Mohammad A1 - Jenkin, Phil A1 - Alsultan, Abdulrahman A1 - Buechner, Jochen A1 - Stein, Jerry A1 - Kelemen, Agnes A1 - Jarisch, Andrea A1 - Soerensen, Jan A1 - Salzmann-Manrique, Emilia A1 - Hutter, Martin A1 - Schäfer, Richard A1 - Seifried, Erhard A1 - Paneesha, Shankara A1 - Novitzky-Basso, Igor A1 - Gefen, Aharon A1 - Nevo, Neta A1 - Beutel, Gernot A1 - Schlegel, Paul-Gerhardt A1 - Klingebiel, Thomas A1 - Bader, Peter T1 - Children and adults with Refractory acute Graft-versus-Host Disease respond to treatment with the Mesenchymal Stromal cell preparation “MSC-FFM”—Outcome report of 92 patients JF - Cells N2 - (1) Background: Refractory acute graft-versus-host disease (R-aGvHD) remains a leading cause of death after allogeneic stem cell transplantation. Survival rates of 15% after four years are currently achieved; deaths are only in part due to aGvHD itself, but mostly due to adverse effects of R-aGvHD treatment with immunosuppressive agents as these predispose patients to opportunistic infections and loss of graft-versus-leukemia surveillance resulting in relapse. Mesenchymal stromal cells (MSC) from different tissues and those generated by various protocols have been proposed as a remedy for R-aGvHD but the enthusiasm raised by initial reports has not been ubiquitously reproduced. (2) Methods: We previously reported on a unique MSC product, which was generated from pooled bone marrow mononuclear cells of multiple third-party donors. The products showed dose-to-dose equipotency and greater immunosuppressive capacity than individually expanded MSCs from the same donors. This product, MSC-FFM, has entered clinical routine in Germany where it is licensed with a national hospital exemption authorization. We previously reported satisfying initial clinical outcomes, which we are now updating. The data were collected in our post-approval pharmacovigilance program, i.e., this is not a clinical study and the data is high-level and non-monitored. (3) Results: Follow-up for 92 recipients of MSC-FFM was reported, 88 with GvHD ≥°III, one-third only steroid-refractory and two-thirds therapy resistant (refractory to steroids plus ≥2 additional lines of treatment). A median of three doses of MSC-FFM was administered without apparent toxicity. Overall response rates were 82% and 81% at the first and last evaluation, respectively. At six months, the estimated overall survival was 64%, while the cumulative incidence of death from underlying disease was 3%. (4) Conclusions: MSC-FFM promises to be a safe and efficient treatment for severe R-aGvHD. KW - graft-versus host KW - transplantation KW - mesenchymal stromal cell KW - cell therapy KW - hospital exemption KW - steroid-resistant aGvHD KW - refractory aGvHD Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-193878 SN - 2073-4409 VL - 8 IS - 12 ER - TY - JOUR A1 - Kerwagen, Fabian A1 - Riemer, Uwe A1 - Wachter, Rolf A1 - von Haehling, Stephan A1 - Abdin, Amr A1 - Böhm, Michael A1 - Schulz, Martin A1 - Störk, Stefan T1 - Impact of the COVID-19 pandemic on implementation of novel guideline-directed medical therapies for heart failure in Germany: a nationwide retrospective analysis JF - The Lancet Regional Health - Europe N2 - Background Guideline-directed medical therapy (GDMT) is the cornerstone in the treatment of patients with heart failure and reduced ejection fraction (HFrEF) and novel substances such as sacubitril/valsartan (S/V) and sodium-glucose co-transporter-2 inhibitors (SGLT2i) have demonstrated marked clinical benefits. We investigated their implementation into real-world HF care in Germany before, during, and after the COVID-19 pandemic period. Methods The IQVIA LRx data set is based on ∼80% of 73 million people covered by the German statutory health insurance. Prescriptions of S/V were used as a proxy for HFrEF. Time trends were analysed between Q1/2016 and Q2/2023 for prescriptions for S/V alone and in combination therapy with SGLT2i. Findings The number of patients treated with S/V increased from 5260 in Q1/2016 to 351,262 in Q2/2023. The share of patients with combination therapy grew from 0.6% (29 of 5260) to 14.2% (31,128 of 219,762) in Q2/2021, and then showed a steep surge up to 54.8% (192,429 of 351,262) in Q2/2023, coinciding with the release of the European Society of Cardiology (ESC) guidelines for HF in Q3/2021. Women and patients aged >80 years were treated less often with combined therapy than men and younger patients. With the start of the COVID-19 pandemic, the number of patients with new S/V prescriptions dropped by 17.5% within one quarter, i.e., from 26,855 in Q1/2020 to 22,145 in Q2/2020, and returned to pre-pandemic levels only in Q1/2021. Interpretation The COVID-19 pandemic was associated with a 12-month deceleration of S/V uptake in Germany. Following the release of the ESC HF guidelines, the combined prescription of S/V and SGLT2i was readily adopted. Further efforts are needed to fully implement GDMT and strengthen the resilience of healthcare systems during public health crises. KW - health policy KW - oncology KW - internal medicine KW - heart failure KW - COVID-19 KW - sacubitril-valsartan KW - sodium-glucose co-transporter-2 inhibitors KW - guideline-directed medical therapy KW - evidence-based practice KW - real-world Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-350510 SN - 2666-7762 VL - 35 ER -